Drugs / TrasGEX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01409343 | Jul 2011 → Nov 2013 | cancer | Glycotope GmbH | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TrasGEX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01409343 ↗ |
| Modality | Monoclonal antibody | “a glyco-optimised anti-HER2 monoclonal antibody” PMID 30018811 ↗ Jun 2018 |
| Route | Intravenous | “received TrasGEX intravenously every 3 weeks” NCT01409343 ↗ |